Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals (NASDAQ:CTXR) reported its fiscal Q3 2025 results and provided updates on its transition to a commercial organization. The company secured $12.5 million in gross financings during Q3, with an additional $9 million raised by Citius Oncology in July 2025.
Key financial metrics include a net loss of $9.2 million ($0.80 per share), reduced from $10.6 million in Q3 2024. R&D expenses decreased to $1.6 million from $2.8 million year-over-year, while G&A expenses declined to $4.4 million from $4.8 million. The company ended the quarter with $6.1 million in cash.
Citius is preparing for the U.S. launch of LYMPHIR鈩� in Q4 2025 for cutaneous T-cell lymphoma treatment, having completed commercial-scale manufacturing, labeling, packaging, and distribution agreements.
Citius Pharmaceuticals (NASDAQ:CTXR) ha comunicato i risultati del terzo trimestre fiscale 2025 e ha fornito aggiornamenti sulla transizione verso un'organizzazione commerciale. La societ脿 ha ottenuto $12.5 million in gross financings durante il terzo trimestre, con ulteriori $9 million raccolti da Citius Oncology a luglio 2025.
I principali indicatori finanziari includono una perdita netta di $9.2 million (0,80 dollari per azione), in diminuzione rispetto a $10.6 million nel terzo trimestre 2024. Le spese per R&S sono diminuite a $1.6 million da $2.8 million anno su anno, mentre le spese generali e amministrative sono scese a $4.4 million da $4.8 million. La societ脿 ha chiuso il trimestre con $6.1 million in cash.
Citius si sta preparando per il lancio negli Stati Uniti di LYMPHIR鈩� nel quarto trimestre 2025 per il trattamento del linfoma cutaneo a cellule T, avendo completato la produzione su scala commerciale, l'etichettatura, il confezionamento e gli accordi di distribuzione.
Citius Pharmaceuticals (NASDAQ:CTXR) anunci贸 sus resultados del tercer trimestre fiscal de 2025 y ofreci贸 actualizaciones sobre su transici贸n a una organizaci贸n comercial. La compa帽铆a asegur贸 $12.5 million in gross financings durante el tercer trimestre, con otros $9 million recaudados por Citius Oncology en julio de 2025.
Los principales indicadores financieros incluyen una p茅rdida neta de $9.2 million (0,80 d贸lares por acci贸n), reducida desde $10.6 million en el tercer trimestre de 2024. Los gastos de I+D descendieron a $1.6 million desde $2.8 million interanual, mientras que los gastos generales y administrativos bajaron a $4.4 million desde $4.8 million. La compa帽铆a cerr贸 el trimestre con $6.1 million in cash.
Citius se prepara para el lanzamiento en EE. UU. de LYMPHIR鈩� en el cuarto trimestre de 2025 para el tratamiento del linfoma cut谩neo de c茅lulas T, habiendo completado la fabricaci贸n a escala comercial, el etiquetado, el envasado y los acuerdos de distribuci贸n.
Citius Pharmaceuticals (NASDAQ:CTXR)電� 2025 須岅硠鞐半弰 3攵勱赴 鞁れ爜鞚� 氚滍憸頃橁碃 靸侅梾 臁办鞙茧鞚� 鞝勴櫂鞐� 雽�頃� 鞐呺嵃鞚错姼毳� 鞝滉车頄堨姷雼堧嫟. 須岇偓電� 3攵勱赴 霃欖晥 $12.5 million in gross financings鞚� 頇曤炒頄堦碃, 2025雲� 7鞗� Citius Oncology臧� 於旉皜搿� $9 million鞚� 臁半嫭頄堨姷雼堧嫟.
欤检殧 鞛 歆�響滊電� $9.2 million鞚� 靾滌啇鞁�(欤茧嫻 $0.80)鞚� 鞛堨棃鞙茧┌, 鞚措姅 2024雲� 3攵勱赴鞚� $10.6 million鞐愳劀 臧愳唽頃� 靾橃箻鞛呺媹雼�. 鞐瓣惮臧滊皽牍勲姅 鞐瓣皠 旮办鞙茧 $2.8 million鞐愳劀 $1.6 million鞙茧 欷勳棃瓿�, 鞚茧皹甏�毽箘電� $4.8 million鞐愳劀 $4.4 million鞙茧 臧愳唽頄堨姷雼堧嫟. 攵勱赴 毵� 順勱笀鞚� $6.1 million in cash鞚� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�.
Citius電� 頂茧秬 T靹疙彫 毽柬攧膦� 旃橂毳� 鞙勴暅 LYMPHIR鈩㈧潣 氙戈淡 於滌嫓毳� 2025雲� 4攵勱赴鞐� 欷�牍� 欷戩澊氅�, 靸侅梾 攴滊鞚� 鞝滌“, 霛茧波毵�, 韽灔 氚� 鞙犿喌 瓿勳暯鞚� 鞕勲頄堨姷雼堧嫟.
Citius Pharmaceuticals (NASDAQ:CTXR) a publi茅 ses r茅sultats du troisi猫me trimestre fiscal 2025 et a fourni des mises 脿 jour sur sa transition vers une organisation commerciale. La soci茅t茅 a obtenu $12.5 million in gross financings au cours du troisi猫me trimestre, avec $9 million suppl茅mentaires lev茅s par Citius Oncology en juillet 2025.
Les principaux indicateurs financiers incluent une perte nette de $9.2 million (0,80 $ par action), en baisse par rapport 脿 $10.6 million au T3 2024. Les d茅penses de R&D ont diminu茅 脿 $1.6 million contre $2.8 million d'une ann茅e sur l'autre, tandis que les frais G&A ont recul茅 脿 $4.4 million contre $4.8 million. La soci茅t茅 a termin茅 le trimestre avec $6.1 million in cash.
Citius se pr茅pare au lancement aux 脡tats-Unis de LYMPHIR鈩� au T4 2025 pour le traitement du lymphome cutan茅 脿 cellules T, ayant finalis茅 la fabrication 脿 茅chelle commerciale, l'茅tiquetage, l'emballage et les accords de distribution.
Citius Pharmaceuticals (NASDAQ:CTXR) meldete seine Ergebnisse f眉r das dritte Quartal des Gesch盲ftsjahres 2025 und gab Updates zur Umstellung auf eine kommerzielle Organisation. Das Unternehmen sicherte sich im dritten Quartal $12.5 million in gross financings, zus盲tzlich wurden im Juli 2025 von Citius Oncology $9 million aufgenommen.
Wichtige Finanzkennzahlen umfassen einen Nettoverlust von $9.2 million (0,80 USD je Aktie), verringert gegen眉ber $10.6 million im dritten Quartal 2024. Die F&E-Ausgaben sanken von $2.8 million auf $1.6 million, w盲hrend die Verwaltungs- und Vertriebskosten von $4.8 million auf $4.4 million zur眉ckgingen. Das Unternehmen schloss das Quartal mit $6.1 million in cash ab.
Citius bereitet den US-Start von LYMPHIR鈩� im vierten Quartal 2025 f眉r die Behandlung des kutanen T-Zell-Lymphoms vor und hat die kommerzielle Produktion, Etikettierung, Verpackung und Vertriebsvereinbarungen abgeschlossen.
- None.
- Significant ongoing net losses of $9.2M in Q3
- Low cash position of $6.1M relative to operational needs
- Continued reliance on external financing through equity and debt
- Stock-based compensation remains high at $2.7M
Insights
Citius secures $21.5M in capital while reducing losses, preparing for critical Q4 2025 LYMPHIR commercial launch in CTCL.
Citius Pharmaceuticals' fiscal Q3 2025 results reveal a company at a pivotal inflection point, transitioning from development to commercialization with its lead asset LYMPHIR. The company has strategically secured
The financial metrics show improved capital efficiency with R&D expenses decreasing
The LYMPHIR launch represents Citius' potential transformation into a revenue-generating entity, addressing an underserved population with cutaneous T-cell lymphoma. The company has completed key pre-launch activities including commercial-scale manufacturing, labeling, packaging, and distribution agreements. Meanwhile, Mino-Lok remains in the pipeline with ongoing FDA discussions, though its timeline appears secondary to the imminent LYMPHIR commercialization.
The recent reverse stock split (implied by the adjusted per-share figures) and multiple capital raises suggest financial challenges, but the strategic focus on commercialization rather than continued R&D spending indicates management is prioritizing the transition to becoming a commercial-stage company. The next two quarters will be decisive as Citius executes its LYMPHIR launch strategy with its newly secured capital.
"During the third quarter, Citius advanced its strategic priorities, and we believe we are now operationally positioned to transition from a development-stage enterprise to a fully integrated commercial organization. Final preparations are underway by our oncology subsidiary for the planned
"In June 2025, we completed a
FISCAL THIRD QUARTER 2025 FINANCIAL RESULTS:
- R&D expenses were
$1.6 million $2.8 million - G&A expenses were
$4.4 million $4.8 million - Stock-based compensation expense was
$2.7 million $3.1 million - Net loss was
$9.2 million $0.80 $10.6 million $1.57 - At June 30, 2025, Citius Pharma had cash and cash equivalents of
$6.1 million $16.5 million $1 million - On July 17, 2025, Citius Oncology completed a public offering generating net proceeds of approximately
$7.4 million
For a complete discussion of our financial results, please refer to our Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed today with the SEC and available at .
About Citius Pharmaceuticals, Inc.
Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR鈩�, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok庐, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. Citius Pharma owns
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting听Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.听 Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our need for substantial additional funds and our ability to raise additional money to fund our operations beyond September 2025 and for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR, including covering the costs of licensing payments, product manufacturing and other third-party goods and services, through our majority-owned subsidiary and any of our other product candidates that may be approved by the FDA; our ability to maintain compliance with Nasdaq's continued listing standards; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market, economic and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC 听filings which are available on the SEC's website at , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024, filed with the SEC on December 27, 2024, as amended on January 27, 2025, Citius Pharma's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 12, 2025, and as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Investor Contact:
Ilanit Allen
[email protected]
908-967-6677 x113
Media Contact:
STiR-communications
Greg Salsburg
[email protected]听
-- Financial Tables Follow 鈥�
听
CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||||||
June 30, | September 30, | |||||||
2025 | 2024 | |||||||
ASSETS | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 6,089,126 | $ | 3,251,880 | ||||
Inventory | 17,208,967 | 8,268,766 | ||||||
Prepaid expenses | 1,313,176 | 2,700,000 | ||||||
Total Current Assets | 24,611,269 | 14,220,646 | ||||||
Operating lease right-of-use asset, net | 880,732 | 246,247 | ||||||
Deposits | 38,062 | 38,062 | ||||||
In-process research and development | 92,800,000 | 92,800,000 | ||||||
Goodwill | 9,346,796 | 9,346,796 | ||||||
Total Other Assets | 102,184,858 | 102,184,858 | ||||||
Total Assets | $ | 127,676,859 | $ | 116,651,751 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current Liabilities: | ||||||||
Accounts payable | $ | 10,094,042 | $ | 4,927,211 | ||||
License payable | 28,400,000 | 28,400,000 | ||||||
Accrued expenses | 8,523,675 | 17,027 | ||||||
Accrued compensation | 3,710,041 | 2,229,018 | ||||||
Note payable | 1,000,000 | - | ||||||
Operating lease liability | 114,694 | 241,547 | ||||||
Total Current Liabilities | 51,842,452 | 35,814,803 | ||||||
Deferred tax liability | 7,506,520 | 6,713,800 | ||||||
Operating lease liability - noncurrent | 766,957 | 21,318 | ||||||
Total Liabilities | 60,115,929 | 42,549,921 | ||||||
Commitments and Contingencies | ||||||||
Stockholders' Equity: | ||||||||
Preferred stock - and outstanding | - | - | ||||||
Common stock - 14,475,029 and 7,247,243 shares issued and outstanding at June 30, 2025 and September 30, 2024, respectively | 14,475 | 7,247 | ||||||
Additional paid-in capital | 295,888,916 | 271,440,421 | ||||||
Accumulated deficit | (230,844,841) | (201,370,218) | ||||||
Total Citius Pharmaceuticals, Inc. Stockholders' Equity | 65,058,550 | 70,077,450 | ||||||
Non-controlling interest | 2,502,380 | 4,024,380 | ||||||
Total Equity | 67,560,930 | 74,101,830 | ||||||
Total Liabilities and Equity | $ | 127,676,859 | $ | 116,651,751 | ||||
Reflects a 1-for-25 reverse stock split effective November 25, 2024. | ||||||||
听
CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2025 AND 2024 (Unaudited) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
June 30, | June 30, | June 30, | June 30, | |||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Revenues | $ | 鈥� | $ | 鈥� | $ | 鈥� | $ | 鈥� | ||||||||
Operating Expenses | ||||||||||||||||
Research and development | 1,621,325 | 2,763,865 | 7,514,888 | 8,991,673 | ||||||||||||
General and administrative | 4,447,008 | 4,808,551 | 14,626,882 | 12,755,190 | ||||||||||||
Stock-based compensation 鈥� general and administrative | 2,719,674 | 3,061,763 | 7,946,529 | 9,198,340 | ||||||||||||
Total Operating Expenses | 8,788,007 | 10,634,179 | 30,088,299 | 30,945,203 | ||||||||||||
Operating Loss | (8,788,007) | (10,634,179) | (30,088,299) | (30,945,203) | ||||||||||||
Other Income (Expense) | ||||||||||||||||
Interest income | 20,637 | 204,843 | 56,658 | 640,686 | ||||||||||||
Gain on sale of | 鈥� | 鈥� | 鈥� | 2,387,842 | ||||||||||||
Interest expense | (172,262) | 鈥� | (172,262) | 鈥� | ||||||||||||
Total Other听Income (Expense) | (151,625) | 204,843 | (115,604) | 3,028,528 | ||||||||||||
Loss before Income Taxes | (8,939,632) | (10,429,336) | (30,203,903) | (27,916,675) | ||||||||||||
Income tax expense | 264,240 | 144,000 | 792,720 | 432,000 | ||||||||||||
Net Loss | (9,203,872) | (10,573,336) | (30,996,623) | (28,348,675) | ||||||||||||
Deemed dividend on warrant extension | 鈥� | 321,559 | 鈥� | 321,559 | ||||||||||||
Net loss attributable to non-controlling interest | 414,000 | 鈥� | 1,522,000 | 鈥� | ||||||||||||
Net loss applicable to common stockholders | $ | (8,789,872) | $ | (10,894,895) | $ | (29,474,623) | $ | (28,670,234) | ||||||||
Net Loss Per Share - Basic and Diluted | $ | (0.80) | $ | (1.57) | $ | (3.27) | $ | (4.37) | ||||||||
Weighted Average Common Shares Outstanding | ||||||||||||||||
Basic and diluted | 11,006,896 | 6,954,278 | 9,020,356 | 6,557,892 | ||||||||||||
Reflects a 1-for-25 reverse stock split effective November 25, 2024. | ||||||||||||||||
听
CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED JUNE 30, 2025 AND 2024 (Unaudited) | ||||||||
2025 | 2024 | |||||||
Cash Flows From Operating Activities: | ||||||||
Net loss | $ | (30,996,623) | $ | (28,348,675) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Stock-based compensation expense | 7,946,529 | 9,198,340 | ||||||
Issuance of common stock for services | 鈥� | 284,175 | ||||||
Amortization of operating lease right-of-use asset | 152,212 | 154,494 | ||||||
Depreciation | 鈥� | 1,432 | ||||||
Deferred income tax expense | 792,720 | 432,000 | ||||||
Changes in operating assets and liabilities: | ||||||||
Inventory | (8,940,201) | 鈥� | ||||||
Prepaid expenses | 1,386,824 | (2,205,091) | ||||||
Accounts payable | 5,166,831 | (1,263,998) | ||||||
Accrued expenses | 8,506,648 | 74,185 | ||||||
Accrued compensation | 1,481,023 | (454,315) | ||||||
Operating lease liability | (167,911) | (161,234) | ||||||
Net Cash Used In Operating Activities | (14,671,948) | (22,288,687) | ||||||
Cash Flows From Financing Activities: | ||||||||
Net proceeds from common stock offerings | 16,509,194 | 13,718,951 | ||||||
听听听听Proceeds from sale of Series A preferred stock | 100 | 鈥� | ||||||
听听听听Redemption of Series A preferred stock | (100) | 鈥� | ||||||
听听听听Proceeds from note payable and advance from employee | 1,300,000 | 鈥� | ||||||
听听听听Repayment of advance from employee | (300,000) | 鈥� | ||||||
Net Cash Provided By Financing Activities | 17,509,194 | 13,718,951 | ||||||
Net Change in Cash and Cash Equivalents | 2,837,246 | (8,569,736) | ||||||
Cash and Cash Equivalents - Beginning of Period | 3,251,880 | 26,480,928 | ||||||
Cash and Cash Equivalents - End of Period | $ | 6,089,126 | $ | 17,911,192 | ||||
Supplemental Disclosures of Cash Flow Information and Non-cash Transactions: | ||||||||
Operating lease right-of-use asset and liability recorded | $ | 786,697 | $ | 鈥� | ||||
听
听
View original content to download multimedia:
SOURCE Citius Pharmaceuticals, Inc.
FAQ
What were Citius Pharmaceuticals (CTXR) Q3 2025 financial results?
When is CTXR planning to launch LYMPHIR?
How much funding did Citius Pharmaceuticals raise in Q3 2025?
What is the status of Citius Pharmaceuticals' commercial preparation?
How much additional funding did Citius Oncology secure in July 2025?
